Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients
Status:
Withdrawn
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and to determine the Dose Limiting
Toxicity (DLT) and the Maximal Tolerated Dose (MTD) of KAHR-102.